Synthesis of isosorbide: an overview of challenging reactions

New Drug Approvals

Green Chem., 2017, Advance Article
DOI: 10.1039/C7GC01912B, Tutorial Review
C. Dussenne, T. Delaunay, V. Wiatz, H. Wyart, I. Suisse, M. Sauthier
This review gives an overview of the catalysts and technologies developed for the synthesis of isosorbide, a platform molecule derived from biomass (sorbitol and cellulose).

Synthesis of isosorbide: an overview of challenging reactions

 Author affiliations

View original post 1,243 more words

Advertisements

ELAMIPRETIDE

New Drug Approvals

Elamipretide.pngimg

Elamipretide

Elamipretide biologic depiction

H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2

D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide

(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide

CAS 736992-21-5

Chemical Formula: C32H49N9O5

Molecular Weight: 639.8

  • A free radical scavenger and antioxidant that localizes in the inner mitochondrial membrane.
  • Mitochondrial Protective Agent to Improve Cell Viability
  1. Elamipretide
  2. bendavia
  3. UNII-87GWG91S09
  4. 736992-21-5
  5. MTP 131
  6. RX 31
  7. SS 31
  8. 87GWG91S09
  9. L-Phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-
  10. SS-31 peptide
  11. Arg-Dmt-Lys-Phe-NH2
  12. D-Arg-Dmt-Lys-Phe-NH2
  13. SS31 peptide
  14. Elamipretide [USAN:INN]
  15. MTP-131
  16. Elamipretide (USAN/INN)
  17. arginyl-2,’6′-dimethyltyrosyl-lysyl-phenylalaninamide
  18. CHEMBL3833370
  19. SCHEMBL15028020
  20. CTK2H1007

Elamipretide (also known as SS-31 and Bendavia)[1][2] is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.[3]

Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics.[4][5]Acute coronary syndrome; Age related macular degeneration; Cardiac failure; Corneal dystrophy; Diabetic macular edema; Lebers hereditary optic atrophy

  • Originator Stealth Peptides
  • Developer Stealth BioTherapeutics
  • Class Eye disorder therapies; Ischaemic…

View original post 3,340 more words

Total CCl4 guest alignment in a quasiracemic clathrate closely related to Dianin’s compound

CrystEngComm, 2017, 19,5703-5706
DOI: 10.1039/C7CE01275F, Communication
Christopher S. Frampton, James H. Gall, David D. MacNicol
In the trigonal CCl4quasiracemic clathrate, space group R3, formed from host components S-(-)-Dianin’s compound, 4, and its (+)-2R,4R 2-nor methyl analogue, 2, the unprecedented complete ordering of a C-Cl bond of the guest with respect to the c-axial direction and the participation of an unexpected host conformation is reported for the first time.

Total CCl4 guest alignment in a quasiracemic clathrate closely related to Dianin’s compound

 Author affiliations

Abstract

Single crystal X-ray analysis at 100 K reveals that in the trigonal CCl4quasiracemic clathrate, space group R3, formed from host components S-(−)-Dianin’s compound and its (+)-2R,4R 2-nor methyl analogue there is an unprecedented complete ordering of a C–Cl bond of the guest with respect to the c-axial direction. In this clathrate and that formed from the (+)-2R,4R and (+)-2R,4S epimers the participation of an unexpected host conformation is reported for the first time.

////////////